Posted on 12 July 2019
The decision to shut down sales of Watson for Drug Discovery marks the highest-profile retreat in the company’s effort to apply artificial intelligence to various areas of health care.
Last year, the company scaled back on the hospital side of its business, and it’s struggled to develop a reliable tool to assist doctors in treating cancer patients.
According to the IEEE Spectrum report, IBM’s entire foray into health care has been marked by the familiar combination of overpromising and under-delivery.
Also last year there was the fiasco of IBM Watson reportedly recommending cancer treatments that were ‘unsafe and incorrect’